Search

Your search keyword '"Krishna Akella"' showing total 2 results
Start Over Author "Krishna Akella" Publisher elsevier
2 results on '"Krishna Akella"'

1. Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis

Author

Ghulam Murtaza, Mohit K. Turagam, Jalaj Garg, Urooge Boda, Krishna Akella, Poonam Velagapudi, Andrea Natale, Rakesh Gopinathannair, and Dhanunjaya Lakkireddy

Subjects
Apixaban, Warfarin, Dialysis, End-stage renal disease, Meta-analysis, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background: Warfarin is traditionally the drug of choice for stroke prophylaxis or treatment of venous thromboembolism in patients with end-stage renal disease (ESRD) on hemodialysis as data on apixaban use is scarce. We aimed to assess the safety and efficacy of Apixaban in patients with ESRD on hemodialysis when compared with warfarin. Methods: A comprehensive literature search in PubMed, Google Scholar, and Cochrane databases from inception until Nov 25, 2019, was performed. Studies reporting clinical outcomes comparing Apixaban (2.5 mg BID or 5 mg BID) versus Warfarin in ESRD patients on hemodialysis were included. Mantel-Haenszel risk ratio (RR) random-effects model was used to summarize data. Results: Four studies (three retrospective and one randomized) with a total of 9862 patients (apixaban = 2,547, warfarin = 7315) met inclusion criteria. The overall mean age was 66.6 ± 3.9 years and mean CHA2DS2-VASc score 4.56 ± 0.58. Apixaban was associated with lower rates of major bleeding (RR 0.53, 95% CI 0.45–0.64, p

Published
2021
Full Text
View/download PDF

2. Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis

Author

Mohit K. Turagam, Jalaj Garg, Urooge Boda, Poonam Velagapudi, Dhanunjaya Lakkireddy, Krishna Akella, Rakesh Gopinathannair, Ghulam Murtaza, and Andrea Natale

Subjects
medicine.medical_specialty, medicine.medical_treatment, 030204 cardiovascular system & hematology, End stage renal disease, 03 medical and health sciences, End-stage renal disease, 0302 clinical medicine, Physiology (medical), Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, Apixaban, 030212 general & internal medicine, Stroke, Dialysis, business.industry, Warfarin, Atrial fibrillation, medicine.disease, Meta-analysis, Relative risk, RC666-701, Original Article, Hemodialysis, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background: Warfarin is traditionally the drug of choice for stroke prophylaxis or treatment of venous thromboembolism in patients with end-stage renal disease (ESRD) on hemodialysis as data on apixaban use is scarce. We aimed to assess the safety and efficacy of Apixaban in patients with ESRD on hemodialysis when compared with warfarin. Methods: A comprehensive literature search in PubMed, Google Scholar, and Cochrane databases from inception until Nov 25, 2019, was performed. Studies reporting clinical outcomes comparing Apixaban (2.5 mg BID or 5 mg BID) versus Warfarin in ESRD patients on hemodialysis were included. Mantel-Haenszel risk ratio (RR) random-effects model was used to summarize data. Results: Four studies (three retrospective and one randomized) with a total of 9862 patients (apixaban = 2,547, warfarin = 7315) met inclusion criteria. The overall mean age was 66.6 ± 3.9 years and mean CHA2DS2-VASc score 4.56 ± 0.58. Apixaban was associated with lower rates of major bleeding (RR 0.53, 95% CI 0.45–0.64, p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results